News

The decision is based on outcomes from the Phase III CheckMate -9DW trial. According to the outcomes of the trial presented by the company in June last year,

This places the company’s valuation at $525m. Transformation Capital led the funding round, with participation from current investors like World Innovation Lab, OCV Partners, UP2398, Khosla Ventures, Cone

Additionally, the company is on track to submit a marketing authorisation application (MAA) to the European Medicines Agency (EMA) in the first quarter of this year. The Division

Sanofi Ventures and EQT Life Sciences jointly led the funding round. New investors like Novartis Venture Fund, RiverVest Venture Partners, Mirae Asset Financial Group, abrdn-managed funds, GHR Foundation,

Utilising its collaboration with Microsoft and a team of multidisciplinary scientists, the company is poised to disrupt the conventional therapeutic discovery model. The company was co-founded by Dr

The application is currently being evaluated by the EMA’s Committee for Medicinal Products for Human Use (CHMP). Mavorixafor would become the first drug for this syndrome in the European

Memantine/donepezil 14-10 mg and 28-10 mg capsules are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. This product, referencing NAMZARIC of AbbVie, has

Nearly $25m of the revenue is anticipated for the products under this contract. A human rabies immune globulin (HRIG), KAMRAB is designed for passive, transient post-exposure prophylaxis (PEP)

Designed to target oxidative stress related to RP, NPI-001 is the company’s investigational candidate. In preclinical studies, the therapy improved glutathione, which is said to be the most